ReviewPediatric nephrology (Berlin, Germany)2015
Metabolomics in pediatric nephrology: emerging concepts.
Review in Pediatric nephrology (Berlin, Germany), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Renal dysplasia development and chronic kidney disease.Pediatric research · 2025Review
- Consistency of metabolite associations with measured glomerular filtration rate in children and adults.Clinical kidney journal · 2024Article
- Crosstalk between COVID-19 Infection and Kidney Diseases: A Review on the Metabolomic Approaches.Vaccines · 2023Review
- Using Machine Learning to Identify Metabolomic Signatures of Pediatric Chronic Kidney Disease Etiology.Journal of the American Society of Nephrology : JASN · 2022Article
- New Insights from Metabolomics in Pediatric Renal Diseases.Children (Basel, Switzerland) · 2022Review
- Acute Kidney Injury and Pediatric Bone Health.Frontiers in pediatrics · 2020Review
- Insights into the Chemical Biology of Childhood Embryonal Solid Tumors by NMR-Based Metabolomics.Biomolecules · 2019Review
- The nephrologist of tomorrow: towards a kidney-omic future.Pediatric nephrology (Berlin, Germany) · 2017Review
- Preterm neonatal urinary renal developmental and acute kidney injury metabolomic profiling: an exploratory study.Pediatric nephrology (Berlin, Germany) · 2017Article
- Techniques and Approaches to Genetic Analyses in Nephrological Disorders.Journal of pediatric genetics · 2016Review
- Metabolomics and renal disease.Current opinion in nephrology and hypertension · 2015 · on this mapReview
- Drug-induced renal damage in preterm neonates: state of the art and methods for early detection.Drug safety · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Metabolomics, the latest of the "omics" sciences, refers to the systematic study of metabolites and their changes in biological samples due to physiological stimuli and/or genetic modification. Because metabolites represent the downstream expression of genome, transcriptome, and proteome, they can closely reflect the phenotype of an organism at a specific time. As an emerging field in analytical biochemistry, metabolomics has the potential to play a major role in monitoring real-time kidney function and detecting adverse renal events. Additionally, small molecule metabolites can provide mechanistic insights into novel biomarkers of kidney diseases, given the limitations of the current traditional markers. The clinical utility of metabolomics in the field of pediatric nephrology includes biomarker discovery, defining as yet unrecognized biological therapeutic targets, linking of metabolites to relevant standard indices and clinical outcomes, and providing a window of opportunity to investigate the intricacies of environment/genetic interplay in specific disease states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.